Efficacy and Safety of Tofacitinib in the Treatment of Adults With Lichen Planopilaris: A Randomized Placebo-Controlled Trial Publisher Pubmed



H Mahmoudi HAMIDREZA ; M Daneshpajooh MARYAM ; S Dadkhahfar SAHAR ; Rm Robati R M ; Z Tehranchinia ZOHREH ; P Farokh PARISA ; M Shariatnia MOHAMMAD ; M Shahididadras MOHAMMAD ; H Moravvejfarshi HAMIDEH
Source: International Immunopharmacology Published:2025

Abstract

Background: Lichen planopilaris (LPP) is a chronic inflammatory disorder that affects hair follicles and leads to permanent hair loss. Managing LPP is challenging due to insufficient evidence on treatments' effectiveness. Janus kinase inhibitors have recently emerged as potential therapies for LPP. Objectives: This study aims to evaluate the efficacy of tofacitinib, a JAK inhibitor, compared to placebo in classic LPP. Methods: A randomized, double-blind, placebo-controlled trial was conducted with 37 participants. Participants received either tofacitinib 5 mg daily or placebo along with topical clobetasol for six months. Both groups were followed for nine months. Outcome measures included the Lichen Planopilaris Activity Index, Physician's Global Assessment Score, Dermatology Life Quality Index, and adverse events. Results: Our results demonstrated a significant improvement in the anagen pull test in the tofacitinib group compared to placebo, indicating treatment effectiveness. However, no significant difference was observed in the reduction of the Lichen Planopilaris Activity Index between the two groups. Tofacitinib also showed a significant decrease in physician global assessment scores over time compared to placebo. Adverse events were minimal, with no significant differences between groups. Conclusions: This study suggests that tofacitinib may effectively halt disease progression in LPP, emphasizing its potential as a treatment option. © 2025 Elsevier B.V., All rights reserved.